Hematologic Oncology | Specialty

Changing Therapeutic Landscape in ALL, CLL, and NHL

January 22nd 2014

Combination Therapy in Large Cell Lymphomas

January 22nd 2014

Brentuximab Vedotin in Diffuse Large B-cell Lymphoma

January 22nd 2014

PI3K Inhibition in Hematologic Malignancies

January 22nd 2014

Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas

January 22nd 2014

Combining and Sequencing New Agents in CLL

January 22nd 2014

Efficacy and Future Role of Ibrutinib in CLL and MCL

January 22nd 2014

Surrogate Endpoints for New Drug Discovery in ALL

January 22nd 2014

Emerging Strategies in the Treatment of ALL

January 22nd 2014

Novel Therapies for Patients Ph-Negative ALL

January 22nd 2014

Introduction: Treating ALL in Adult Patients

January 22nd 2014

Dr. Amengual on Novel Therapeutics in Lymphoma

January 21st 2014

Jennifer E. Amengual, MD, discusses the development of novel agents for subtypes of diffuse large b-cell lymphoma.

Anti-PD-1 Antibody Pidilizumab Shows Promise in Diffuse Large B-Cell Lymphoma

January 17th 2014

The anti-PD-1 monoclonal antibody pidilizumab showed promising clinical activity and was safely administered to patients with diffuse large B-cell lymphoma after autologous hematopoietic stem-cell transplantation.

Anti-CD20 Antibodies Continue to Improve Outlook in CLL

January 16th 2014

The FDA approval of two anti-CD20 antibodies-ofatumumab and, recently, obinotuzumab-has greatly advanced the outlook for managing chronic lymphocytic leukemia.

Novel Therapies for T315I-Mutant Chronic Myeloid Leukemia

January 10th 2014

Abelson tyrosine kinase (ABL1) is a nonreceptor tyrosine kinase involved in cell growth and proliferation.

Final Thoughts on Clinical Advances in MDS and CML

January 9th 2014

Oral Azacitidine and Lenalidomide Combinations in MDS

January 9th 2014

Novel Agents and Treatment Strategies in MDS

January 9th 2014

Current and Future Treatment Landscape for MDS

January 9th 2014

Treatment of MDS Refractory to Hypomethylating Agent

January 9th 2014